The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients
Küçük Resim Yok
Tarih
2007
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Pulsus Group Inc
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
BACKGROUND: The aim of the present study was to investigate the effects of nebivolol (5 mg daily) on plasma levels of hemostatic and fibrinolytic endothelial function markers in mild or moderate hypertensive patients. METHODS AND RESULTS: Thirty-five (22 female, 13 male; mean +/- SD 54.7 +/- 11.3 years of age) mild and moderate hypertensive patients were included the study. The mean systolic blood pressure [BP] was 160 mmHg (range 150 mmHg to 165 mmHg) and the mean diastolic BP was 100 mmHg (range 90 mmHg to 100 mmHg). Plasma tissue plasminogen activator antigen (tPA-Ag), plasminogen activator inhibitor type 1 antigen (PAI-1-Ag), PAI-1-activity, tPA-Ag/PAI-1-Ag index, fibrinogen and euglobulin lysis time were determined before and after two months of therapy. tPA-Ag and PAI-Ag levels were measured by ELISA. After this period, treatment with nebivolol (5 mg/day) in all patients was associated with a significant decrease in systolic BP and diastolic BP (P < 0.001 for each), heart rate (P < 0.01), fibrinogen (P < 0.005) and euglobutin lysis time (P < 0.01). The tPA-Ag and tPA-Ag/PAI-1-Ag index levels were increased significantly (P < 0.001 for each) in all patients, but the PAI-1-Ag (P > 0.05) and PAI-1 activity (P > 0.05) did not show significant change. In the present study, there was no correlation between decreases in arterial BP and decreases in fibrinolytic parameters (P > 0.05), but there was a positive, statistically significant correlation between fibrinogen and body mass index (P < 0.001). CONCLUSIONS: The results indicated that, compared with no treatment, a two-month treatment trial with nebivolol was associated with a more favourable modification of hemostatic and fibrinolytic status in addition to antihypertensive effects.
Açıklama
Anahtar Kelimeler
Fibrinolytic System, Hypertension, Nebivolol, Plasminogen-Activator Inhibitor, 3rd-Generation Beta-Blocker, Myocardial-Infarction, Hemostatic Factors, Blood-Pressure, Antihypertensive Treatment, Endothelial Dysfunction, Systemic Hypertension, Prothrombotic State, Plasma-Fibrinogen
Kaynak
Canadian Journal Of Cardiology
WoS Q Değeri
Q3
Scopus Q Değeri
Q1
Cilt
23
Sayı
8
